Precision Across Blood and Tissue
Quanterix advances precision across research and healthcare by transforming biomarker data into meaningful insight; driving discovery, guiding clinical decisions, and accelerating breakthroughs from bench to bedside.
instruments deployed globally
peer-reviewed publications
Partnerships with top 20 pharma, CROs, and diagnostics labs
One Company. Two Modalities. Full-Spectrum Biomarker Clarity
Quanterix delivers matched biomarker insights across blood, CSF and tissue. While liquid assays detect systemic signals, spatial tissue analysis maps those signals to their biological origin.
- Power research in neurology, oncology, inflammation and beyond
- Follow the same biomarker across matrices
- Ready for validated use: CLIA-ready Simoa assays & standardized spatial panels
Dual Modality. Total Insight.
Explore our solutions and services.
Simoa Instruments
From Benchtop to fully automated, our analyzers deliver high throughput biomarker quantification with true pg/mL resolution across matrices.
Simoa Assay Kits and Reagents
Measure low abundance biomarkers with unmatched sensitivity, precision and reproducibility- across neurology, immunology, oncology, and more.
Spatial Biology Instruments
Capture high-plex spatial proteomic data at single cell resolution with imaging platforms designed for translational research and clinical workflows.
Spatial Biology Assays & Reagents
Unlock tissue-based biomarker signatures with high-plex spatial proteomics panels built for discovery, validation, and CDx development.
Simoa® Accelerator Laboratory
Empowering researchers to bring new discoveries in disease and treatment to the forefront with our Simoa precision instruments, wide-ranging menu of assay kits, and custom assay development services.
Lucent Diagnostics
Learn how we’re bringing the power of p-Tau to the clinic with the LucentAD blood test- advancing Alzheimer’s care through precision diagnostics powered by Simoa.
Built for Clinical Rigor. Proven in Practice.
Every Matrix. Every Disease. Every Decision.
Your decisions deserve more than just data; they deserve validated, reproducible insights. Quanterix platforms are built for reliability, precision, and trust.
- Consistent detection, not missed samples
- True pg/mL reporting, no arbitrary units
- <10% CVs across matrices
- Validated for clinical trials and CLIA labs
Data You Can Trust, Decisions You Can Act On
Track neurodegeneration and injury biomarkers to support early detection, disease monitoring, and therapeutic evaluation.
Power oncology research with dual modality data, track systemic immune activation through blood and map the tumor microenvironment in tissue with spatial proteomics.
Profile immune activation and suppression across matrices- quantifying cytokines in blood and characterize immune cell architecture in tissue to reveal disease drivers and treatment effects.
Asses cardiology risk and injury with systemic biomarkers and extend insights with spatial analysis of tissue inflammation and remodeling.
Capture host-pathogen interactions with high sensitivity, viral and cytokine detection in blood, paired with tissue level immune profiling for localized response insights.
Proven. Scalable. Ready Now.
Whether you’re designing a clinical trial, validating a diagnostic, or developing next-gen therapies, Quanterix is your partner in precision biomarker innovation. Together with Akoya, we unify liquid and spatial analysis to give you the clearest picture of disease biology.
Proteomics in Transition: From Discovery to Diagnostic Utility
The promise of proteomics lies in its ability to illuminate disease biology at scale, transform translational research, and guide the development of precision diagnostics and targeted therapies. While genomic technologies…
Built for Translation: Why Simoa Stands Alone in Clinical-Grade Biomarker Measurement
Translating proteomic discovery into clinical action requires more than scale, it demands precision, reproducibility, and quantitative clarity. The Quanterix Simoa® digital immunoassay technology was purpose-built to meet the demands of…
YKL-40 Emerges as a Key Indicator of Neuroinflammatory-Driven Tau Pathology and Brain Atrophy in Alzheimer’s Disease
Alzheimer’s disease (AD) is increasingly understood as a multifaceted disorder involving not only amyloid and tau pathology, but also significant contributions from neuroinflammation and vascular dysfunction. In particular, astrocyte reactivity…
Looking Ahead: Key Takeaways from AAIC 2025
The 2025 Alzheimer’s Association International Conference (AAIC) brought the global neuroscience community to share breakthrough science, policy priorities, and tools like never before. It was an incredible week of conversation, innovation and…
Neurology
AAIC 2025: A Showcase of Simoa-Powered Innovation and Integration in Alzheimer’s Research
Next week, researchers from around the globe will gather in Toronto for the Alzheimer’s Association International Conference (AAIC) 2025, and Quanterix is proud to be at the center of the…
Neurology
Blood-based Brain Injury Biomarkers: Revealing the Hidden Story of Brain Health
Every year, countless individuals experience head injuries, often with effects that linger long after the initial incident. Whether from a fall at home, a fender-bender on the road, or a…
Immunology
Unlocking Ultra-Sensitive Cytokine Detection: Insights from the Frontage & Quanterix Webinar
On June 11, 2025, Quanterix and Frontage Laboratories co-hosted a compelling webinar focused on improving cytokine biomarker quantification using the Simoa® platform. The session featured Jingwen Tan, Ph.D., Director of…
Neurology
Refining the Alzheimer’s Biomarker Framework: Integrating p-Tau 205 and p-Tau 212 for Comprehensive Disease Profiling
Advances in Alzheimer’s biomarker science have transformed early detection and stratification, laying the groundwork for more personalized approaches to care. Yet as the field shifts toward tracking disease dynamics with…
Quanterix Corporation Announces Date of 2026 Annual Meeting
BILLERICA, Mass. — (BUSINESS WIRE) — March 27, 2026 – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection (the “Company”), today announced that the Company’s…
Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025
Reports $43.9 million in revenue and cash balance of $122 million Company expects to achieve cash flow breakeven during 2026 BILLERICA, Mass. – March 2, 2026 – Quanterix Corporation (NASDAQ: QTRX),…
Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide
Collaboration Aims to Expand Access to Early Detection of Potential Disease Marker BILLERICA, Mass. – February 27, 2026 – Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced…
Quanterix to Participate in Upcoming Investor Conferences
BILLERICA, Mass. – February 26, 2026 – Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team…
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026
BILLERICA, Mass. – February 20, 2026 – Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that it will host a…
Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection
Submission utilizes the comprehensive five-analyte panel and algorithm that formed the basis for Quanterix’s LucentAD® Complete LDT BILLERICA, Mass. – February 3, 2026 – Quanterix Corporation (Nasdaq: QTRX), a company…
Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling
Analysis of Subjective Cognitive Decline (SCD) cohort indicates that combining biomarkers representing four key biological axes—amyloid, tau, neurodegeneration, and neuroinflammation—provides a superior window into disease progression at the earliest stages…
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass. – January 16, 2026 – Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on January 15,…
Underdiagnosis of Alzheimer’s disease pathology in patients with cardiovascular disease
Decoding Neurodegeneration: High-plex Spatial Proteomics Reveal Distinct Cell Phenotypes and Pathological Signatures in Parkinson’s and Alzheimer’s Disease
In this webinar, Dr. Birgitt Schuele, Associate Professor (Research) of Pathology at Stanford University, showcases how ultrahigh-plex spatial proteomics is being used to uncover distinct cell phenotypes and pathological signatures…
Understanding the Brain: Advancing Neurodegeneration Research with Ultrahigh-Plex Spatial Proteomics
In this webinar, learn how ultrahigh-plex spatial phenotyping has been applied to neurodegenerative disease research.
p-Tau 205 and p-Tau 212: Emerging Biomarkers for Alzheimer’s Disease Research
Spatial Awareness: AI-powered Profiling of Trillions of Immune Cell Distribution Data Points Reveals Key Predictors of Cancer Recurrence Risk
This webinar highlights a groundbreaking study recently published as a Nature cover story (April 2025). Dr. Joe Yeong will describe how a pre-designed analytical framework—driven by well-defined clinical and scientific…
Multimodal Single-Cell Spatial Transcriptomics and Proteomics to Uncover the Biological Processes Driving Immunotherapy Response and Resistance in Renal Cancer
In this webinar, Dr. Anne-Laure Cattin from the Cancer Dynamics Laboratory at The Francis Crick Institute in London, will share her research on kidney cancer, focusing on the integration of…
Tertiary Lymphoid Structures in Cancer Immunotherapy: Insights and Perspectives
Tertiary lymphoid structures (TLS) have emerged as critical components of the tumor microenvironment, influencing immune responses and clinical outcomes in cancer.
Discover How to Achieve High Sensitivity Cytokine Biomarker Quantification in Complex Samples Using Simoa Assays
Introducing the Metabolism Spike-in Module for IO60
Neurology
NfL Fact Sheet
Neurofilament light (NfL) has emerged in recent years as a blood-based biomarker with the potential to aid in the improvement of early diagnosis and patient care of neuro-axonal injury and…
Neurology
Cytokine 4-Plex Advantage PLUS Product Flyer
Ultra-Sensitive, Fully Automated Simoa® Cytokine 4-Plex Advantage PLUS Assays Three panels, 11 essential cytokine biomarkers, femtogram sensitivity With Simoa® ultra-sensitive protein quantification, the cutting-edge Advantage PLUS assay platform, and full…
PhenoCode Discovery Immune Activation and Proliferation Human Protein Module
Neurology
Brain-Derived Tau (BD-Tau) Fact Sheet
Brain-derived Tau (BD-Tau) is one of the latest additions to the growing neurology biomarker family that holds promise to improve the accuracy in the identification and staging of neurodegeneration in…
Neurology
Simoa® Technology Powering Advancements in Neurology
Flyer Quanterix empowers researchers with cutting-edge Simoa® digital immunoassays that measure both established and emerging biomarkers in neurology. Simoa® technology sets the gold standard for early biomarker detection in serum,…
Immunology
Measure Ultra Low Levels of IFN-α with Simoa® Advantage PLUS
Flyer Unlock new possibilities with Simoa® IFN-α Multi-Subtype (MS) Advantage PLUS, enabling the measurement of circulating IFN-α at femtogram levels. Whether you‘re advancing research on the immune response or evaluating…
Homebrew
Quanterix Accelerator Laboratory Brochure
The Quanterix Accelerator Laboratory is a dedicated laboratory environment for digitized biomarker research, custom assay development, and clinical sample testing using our Simoa® technology. The Quanterix Accelerator Lab offers ultra-sensitive assay…
Resources
Explore our library of resources, posts and materials.
Support
Contact our team for customer support, distributor inquiries, or general questions.